See more : MEC Resources Limited (MMR.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Addex Therapeutics Ltd (ADXN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Addex Therapeutics Ltd, a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Proteak Uno, S.A.B. de C.V. (TEAKCPO.MX) Income Statement Analysis – Financial Results
- Kuniko Limited (KNI.AX) Income Statement Analysis – Financial Results
- Guilin Seamild Foods Co., Ltd (002956.SZ) Income Statement Analysis – Financial Results
- NPC Co., Ltd. (004250.KS) Income Statement Analysis – Financial Results
- Oxford Square Capital Corp. 5.50% Notes due 2028 (OXSQG) Income Statement Analysis – Financial Results
Addex Therapeutics Ltd (ADXN)
About Addex Therapeutics Ltd
Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The CharcotMarieTooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.61M | 1.42M | 2.92M | 3.61M | 2.76M | 6.04M | 499.89K | 17.33K | 40.30K | 85.40K | 91.76K | 121.09K | 2.82M | 1.98M | 4.09M | 26.81M | 486.93K | 4.74M |
| Cost of Revenue | 6.94M | 14.62M | 12.82M | 10.37M | 230.10K | 144.17K | 29.76K | 17.33K | 40.30K | 85.40K | 91.76K | 1.27M | 27.99M | 31.16M | 0.00 | 0.00 | -156.03K | 0.00 |
| Gross Profit | -5.32M | -13.20M | -9.90M | -6.76M | 2.53M | 5.90M | 470.13K | 0.00 | 0.00 | 0.00 | 0.00 | -1.15M | -25.16M | -29.19M | 4.09M | 26.81M | 642.96K | 4.74M |
| Gross Profit Ratio | -329.99% | -928.06% | -339.55% | -187.12% | 91.67% | 97.61% | 94.05% | 0.00% | 0.00% | 0.00% | 0.00% | -948.14% | -891.19% | -1,477.75% | 100.00% | 100.00% | 132.04% | 100.00% |
| Research & Development | 2.75M | 14.67M | 12.84M | 10.37M | 12.45M | 2.37M | 841.31K | 819.33K | 761.22K | 258.06K | 2.22M | 4.76M | 4.76M | 31.16M | 39.96M | 44.19M | 12.21M | 9.77M |
| General & Administrative | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 10.77M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 7.20M | 7.30M | 5.14M | 5.15M | 4.27M | 4.72M | 2.20M | 1.52M | 1.57M | 1.55M | 6.47M | 12.85M | 6.73M | 6.43M | 7.60M | 7.55M | 10.77M | 0.00 |
| Other Expenses | 1.94M | -22.52K | 444.00K | 336.68K | 648.17K | 382.99K | 197.67K | 799.70K | 311.82K | -9.44K | 5.77M | 9.40M | -919.55K | -2.02M | 0.00 | -67.33K | 25.90M | 15.98M |
| Operating Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 5.81M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Cost & Expenses | 11.89M | 21.94M | 18.42M | 15.86M | 17.37M | 7.47M | 3.24M | 3.14M | 2.64M | 1.80M | 14.46M | 27.01M | 33.80M | 35.57M | 47.56M | 51.68M | 38.11M | 25.76M |
| Interest Income | 63.96K | 29.25K | 5.32K | 35.31K | 36.87K | 85.87K | 0.00 | 27.00 | 39.86K | 1.59K | 4.13K | 22.66K | 72.20K | 97.25K | 362.13K | 3.31M | 2.55M | 241.99K |
| Interest Expense | 21.61K | 48.90K | 63.01K | 69.50K | 128.52K | 220.17K | 45.35K | 6.92K | 152.21K | 0.00 | 0.00 | 0.00 | 239.37K | 144.81K | 0.00 | 501.88K | 8.54K | 30.45K |
| Depreciation & Amortization | 305.95K | 323.14K | 347.61K | 378.75K | 333.84K | 2.94K | 15.25K | 25.76K | 25.88K | 110.14K | 662.55K | 2.10M | 2.93M | 2.94M | 2.84M | 2.02M | 1.80M | 2.52M |
| EBITDA | -10.23M | -20.23M | -14.94M | -12.41M | -14.32M | -1.51M | -3.22M | -3.12M | -2.61M | -1.71M | -13.79M | -24.87M | -28.05M | -30.56M | -39.86M | -19.55M | -33.26M | -17.99M |
| EBITDA Ratio | -634.16% | -1,417.83% | -519.59% | -327.42% | -515.18% | -23.52% | -644.10% | -17,979.05% | -6,488.51% | -1,998.26% | -15,026.90% | -20,542.67% | -990.78% | -1,547.10% | 1,112.94% | -72.92% | -6,833.66% | -380.48% |
| Operating Income | -10.28M | -20.52M | -15.51M | -12.24M | -14.83M | -1.42M | -3.24M | -3.13M | -3.87M | -1.80M | -14.46M | -27.01M | -30.97M | -33.60M | -43.05M | -24.87M | -37.62M | -20.90M |
| Operating Income Ratio | -637.42% | -1,442.61% | -531.70% | -338.88% | -536.92% | -23.57% | -647.15% | -18,059.88% | -9,597.64% | -2,103.69% | -15,756.97% | -22,306.25% | -1,097.02% | -1,700.93% | -1,052.47% | -92.78% | -7,726.28% | -441.03% |
| Total Other Income/Expenses | -274.93K | -284.01K | 154.00K | -615.33K | -176.45K | -220.17K | -45.35K | -19.79K | -1.56M | 748.35K | -3.23K | -8.41K | -167.17K | -47.56K | 85.75M | 2.81M | 2.54M | 355.32K |
| Income Before Tax | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -26.61M | -31.14M | -33.65M | 42.69M | -22.07M | -35.09M | -20.54M |
| Income Before Tax Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -21,976.79% | -1,102.95% | -1,703.33% | 1,043.62% | -82.32% | -7,205.50% | -433.53% |
| Income Tax Expense | 0.00 | 123.91K | 116.38K | 207.76K | 429.01K | 1.00 | 0.00 | 6.92K | 152.21K | -21.68K | 3.23K | -398.93K | 72.20K | 97.25K | 171.13M | 3.31M | 2.54M | 346.91K |
| Net Income | -10.56M | -20.80M | -15.35M | -12.86M | -14.78M | -1.64M | -3.28M | -3.15M | -4.20M | -1.77M | -14.46M | -26.61M | -31.14M | -33.65M | -42.69M | -22.07M | -35.09M | -20.54M |
| Net Income Ratio | -654.47% | -1,462.57% | -526.42% | -355.92% | -534.98% | -27.21% | -656.22% | -18,174.08% | -10,432.03% | -2,078.19% | -15,760.49% | -21,976.79% | -1,102.95% | -1,703.33% | -1,043.62% | -82.32% | -7,205.50% | -433.53% |
| EPS | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.36 | -25.14 | -34.12 | -44.67 | -23.08 | -41.96 | -43.11 |
| EPS Diluted | -0.14 | -0.46 | -0.45 | -0.48 | -0.56 | -0.07 | -0.25 | -0.28 | -0.39 | -0.18 | -1.60 | -3.36 | -25.14 | -34.12 | -44.67 | -23.08 | -41.96 | -43.11 |
| Weighted Avg Shares Out | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 1.24M | 986.06K | 955.78K | 956.03K | 836.15K | 476.53K |
| Weighted Avg Shares Out (Dil) | 74.31M | 45.18M | 34.12M | 26.68M | 26.43M | 23.29M | 12.94M | 11.41M | 10.85M | 9.98M | 9.07M | 7.91M | 1.24M | 986.06K | 955.78K | 956.03K | 836.15K | 476.53K |
Enamine Extend Collaboration With Prominent Swiss Biotech
KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world's largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and...
Why Addex, Genetic Technologies And Obalon Are Moving Today
Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone. Genetic Technologies is an Australia-based molecular diagnostics company which offers...
Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is Soaring Today
Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is Soaring Today appeared first on InvestorPlace.
ADXN Stock Price Increases Over 50% Pre-Market: Why It Happened
The stock price of Addex Therapeutics (NASDAQ: ADXN) is trading at more than 50% pre-market today. This is why it happened.
Addex Announces Pricing of $10.0 Million Global Offering
Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the pricing of an underwritten global offering of 6,000,000 registered shares (the New...
The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 24) Avadel Pharmaceuticals PLC (NASDAQ: AVDL ) Brainstorm ...
The Daily Biotech Pulse: FDA Snub For Merck, Priority Review For Roche's Tecentriq sBLA
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 18) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Anavex ...
The Daily Biotech Pulse: Epizyme's Tazemetostat sNDA Accepted For Priority Review, Eisai To Withdraw Weight Loss Drug, Sol-Gel Prices Offering
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 13.) Anavex Life Sciences Corp (NASDAQ: AVXL ) ...
The Daily Biotech Pulse: Deciphera Cancer Drug Gets Priority Review, Fast Track Designation For Soligenix, Revolution Medicines IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 11) AbbVie Inc (NYSE: ABBV ) Acceleron Pharma Inc (NASDAQ: ...
Source: https://incomestatements.info
Category: Stock Reports